Mylan Launches 3 New Generic Drugs
Mylan is launching generic versions of Glucotrol, Axert, and Viramune extended-release tablets.
Mylan is launching generic versions of Glucotrol, Axert, and Viramune extended-release (XR) tablets.
Mylan’s US launch of nevirapine is a generic version of Boehringer Ingelheim’s Viramune XR. Mylan recently received the FDA’s final approval of its abbreviated new drug application (ANDA) for the HIV treatment.
The launch of almotriptan tablets USP, 6.25 mg and 12.5 mg, is a generic version of Janssen Pharmaceutical’s Axert. The tablets are used for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura.
For the fiscal year ending on September 30, 2015, Janssen’s Axert brought in approximately $29 million in total sales, according to IMS Health.
The third generic launch from Mylan is glipizide XR tablets, 5 mg and 10 mg, which is a generic version of Pfizer’s Glucotrol XL. The product is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Mylan now has 253 pending ANDAs representing more than $100 billion in annual brand sales.